デフォルト表紙
市場調査レポート
商品コード
1703460

クラリスロマイシン市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競合別セグメント、2020-2030年

Clarithromycin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
クラリスロマイシン市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競合別セグメント、2020-2030年
出版日: 2025年04月11日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

世界のクラリスロマイシン市場は、2024年に3億1,908万米ドルと評価され、2030年には4億1,490万米ドルに達し、予測期間中に3.90％の複合年間成長率（CAGR）で拡大すると予測されています。

市場成長の主因は、幅広い細菌感染症を対象とした効果的な抗生物質治療に対する需要の高まりです。

市場概要
予測期間 2026-2030
市場規模：2024年 3億1,908万米ドル
市場規模：2030年 4億1,490万米ドル
CAGR：2025年～2030年 3.90%
急成長セグメント ダイレクト
最大市場 アジア太平洋

マクロライド系抗生物質であるクラリスロマイシンは、呼吸器感染症、皮膚感染症、ヘリコバクター・ピロリによる胃潰瘍の治療に広く使用されています。幅広い抗菌薬としての有効性と良好な安全性プロファイルにより、外来・入院を問わず好んで使用される治療薬としての地位を確立しています。

市場拡大を支える重要な要因として、特に大気汚染レベルの高い地域や季節的な気候変動の影響を受ける地域において、肺炎、気管支炎、副鼻腔炎などの呼吸器疾患の罹患率が増加していることが挙げられます。クラリスロマイシンの幅広いグラム陽性菌およびグラム陰性菌を標的とする能力は、これらの疾患の治療プロトコールにおける役割を強化しています。

さらに、特に新興経済諸国におけるヘリコバクター・ピロリ感染症の増加により、クラリスロマイシンをベースとした併用療法の需要が引き続き高まっています。

主な市場促進要因

世界のヘルスケア産業の拡大

主な市場課題

より忍容性の高い代替薬の出現

主要市場動向

呼吸器感染症の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のクラリスロマイシン市場に与える影響

第5章 世界のクラリスロマイシン市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 販売チャネル別（直接、間接）
    • 用途別（肺炎、気管支炎、耳の感染症、皮膚の感染症、咽喉の感染症、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米のクラリスロマイシン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のクラリスロマイシン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域のクラリスロマイシン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米のクラリスロマイシン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのクラリスロマイシン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 世界のクラリスロマイシン市場：SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Ercros S.A
  • Guobang Pharmaceutical Group Co., Ltd
  • Synthimed Labs Private Limited
  • Cipla Ltd
  • Zhejiang Better Pharmaceuticals Co., Ltd.
  • Yichang Dongyang Sunshine Pharmaceutical Co., Ltd
  • Zhejiang Beide Pharmaceutical Co.,Ltd.
  • Huangshi Shi Xing Pharmaceutical Co., Ltd
  • Atom Pharma
  • Alembic Pharmaceuticals Limited

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 28250

The global clarithromycin market was valued at USD 319.08 million in 2024 and is projected to reach USD 414.90 million by 2030, expanding at a compound annual growth rate (CAGR) of 3.90% during the forecast period. Market growth is primarily driven by rising demand for effective antibiotic treatments targeting a wide spectrum of bacterial infections.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 319.08 Million
Market Size 2030USD 414.90 Million
CAGR 2025-20303.90%
Fastest Growing SegmentDirect
Largest MarketAsia-Pacific

Clarithromycin, a macrolide antibiotic, is extensively utilized in the treatment of respiratory tract infections, skin infections, and Helicobacter pylori-induced gastric ulcers. Its broad-spectrum antimicrobial efficacy and favorable safety profile have established it as a preferred therapeutic option across both outpatient and inpatient settings.

A significant factor supporting market expansion is the increasing incidence of respiratory diseases such as pneumonia, bronchitis, and sinusitis, particularly in regions affected by high air pollution levels and seasonal climatic fluctuations. Clarithromycin's ability to target a broad array of Gram-positive and Gram-negative bacteria reinforces its role in treatment protocols for these conditions.

Additionally, the rising burden of Helicobacter pylori infections-especially in developing economies-continues to drive demand for clarithromycin-based combination therapies.

Key Market Drivers

Expansion of the Global Healthcare Industry

The sustained growth of the global healthcare sector is a fundamental driver of the clarithromycin market. Healthcare constitutes one of the largest and fastest-growing industries worldwide. In several developed nations, healthcare spending exceeds 10% of GDP, underlining its economic significance. For example, U.S. healthcare expenditure rose by 2.7% in 2021 to approximately USD 4.3 trillion, averaging USD 12,914 per capita.

As healthcare systems worldwide scale to meet rising patient volumes and adopt evolving treatment protocols, the demand for reliable, broad-spectrum antibiotics such as clarithromycin continues to grow. The antibiotic's widespread use in treating respiratory infections, H. pylori-related conditions, and skin infections positions it to benefit from this sector-wide expansion.

Key Market Challenges

Emergence of Better-Tolerated Alternatives

Despite its established clinical utility, the clarithromycin market is facing growing competitive pressure due to the availability of newer antibiotics with improved tolerability profiles. Although clarithromycin remains a mainstay in treating various infections, the introduction of alternative macrolides and other antibiotic classes is gradually impacting its market share.

Adverse gastrointestinal effects-including nausea, abdominal discomfort, and diarrhea-pose notable concerns with clarithromycin usage. Furthermore, potential drug interactions, particularly among patients on cardiovascular medications, have raised caution among prescribers. As a result, alternatives like azithromycin are increasingly preferred due to their more convenient dosing schedules, reduced risk of drug-drug interactions, and enhanced patient compliance.

Key Market Trends

Increasing Prevalence of Respiratory Infections

The growing prevalence of respiratory infections is a prominent trend influencing demand for clarithromycin. Recognized for its efficacy in managing both upper and lower respiratory tract infections-such as sinusitis, bronchitis, and community-acquired pneumonia-clarithromycin remains a critical therapeutic agent.

Rising pollution levels, urbanization, and climate change have contributed to an increase in respiratory illnesses globally. For instance, in China, influenza is currently the most frequently reported respiratory pathogen in individuals with acute respiratory infections. According to the World Health Organization (WHO), there is no indication of unusual outbreak patterns, and healthcare systems remain within operational capacity. WHO continues to monitor respiratory disease trends globally through established surveillance systems.

Pollutants and fine particulate matter are exacerbating respiratory conditions, increasing population vulnerability to infections. This has led to higher antibiotic prescription rates, with clarithromycin favored due to its broad antimicrobial range and favorable safety profile.

Key Market Players

  • Ercros S.A
  • Guobang Pharmaceutical Group Co., Ltd
  • Synthimed Labs Private Limited
  • Cipla Ltd
  • Zhejiang Better Pharmaceuticals Co., Ltd.
  • Yichang Dongyang Sunshine Pharmaceutical Co., Ltd
  • Zhejiang Beide Pharmaceutical Co.,Ltd.
  • Huangshi Shi Xing Pharmaceutical Co., Ltd
  • Atom Pharma
  • Alembic Pharmaceuticals Limited

Report Scope

In this report, the Global Clarithromycin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clarithromycin Market, By Sales Channel:

  • Direct
  • Indirect

Clarithromycin Market, By End Use:

  • Pneumonia
  • Bronchitis
  • Ear Infection
  • Skin Infection
  • Throat Infection
  • Others

Clarithromycin Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clarithromycin Market.

Available Customizations:

Global Clarithromycin Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Clarithromycin Market

5. Global Clarithromycin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Pneumonia, Bronchitis, Ear Infection, Skin Infection, Throat Infection, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Clarithromycin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Clarithromycin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Clarithromycin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Clarithromycin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Clarithromycin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Clarithromycin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Clarithromycin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Clarithromycin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Clarithromycin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Clarithromycin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Clarithromycin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Clarithromycin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Clarithromycin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Clarithromycin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Clarithromycin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Clarithromycin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Clarithromycin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Clarithromycin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Clarithromycin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Clarithromycin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Clarithromycin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Clarithromycin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Clarithromycin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Clarithromycin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Clarithromycin Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Ercros S.A
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Guobang Pharmaceutical Group Co., Ltd
  • 15.3. Synthimed Labs Private Limited
  • 15.4. Cipla Ltd
  • 15.5. Zhejiang Better Pharmaceuticals Co., Ltd.
  • 15.6. Yichang Dongyang Sunshine Pharmaceutical Co., Ltd
  • 15.7. Zhejiang Beide Pharmaceutical Co.,Ltd.
  • 15.8. Huangshi Shi Xing Pharmaceutical Co., Ltd
  • 15.9. Atom Pharma
  • 15.10. Alembic Pharmaceuticals Limited

16. Strategic Recommendations

17. About Us & Disclaimer